J. W. Clark

1.9k citations

26 papers · 1.5k indexed · 1 hit paper · h-index 15

Pulmonary and Respiratory Medicine top 2%
- Lung Cancer Treatments and Mutations 8
- Gastric Cancer Management and Outcomes 4
Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism 5
- Cancer Genomics and Diagnostics 4
Oncology top 5%
- Colorectal Cancer Treatments and Studies 8
- Pancreatic and Hepatic Oncology Research 3
Endocrinology, Diabetes and Metabolism top 5%
Hepatology top 10%
- Hepatocellular Carcinoma Treatment and Prognosis 3
Molecular Biology
- Molecular Biology Techniques and Applications 2

Co-authors: Stan B. Kaye Timothy A. Yap Johann S. de Bono David P. Dearnaley Colin S. Cooper Elizabeth Folkerd Mitch Dowsett Mary Barrett
Cited by: Pulmonary and Respiratory Medicine Cancer Research Oncology
Journals: Journal of Clinical Oncology (16 papers)Annals of Oncology (2 papers)Science Translational Medicine (1 paper)
Partner nations: United States United Kingdom Myanmar

In The Last Decade

J. W. Clark

25 papers receiving 1.4k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by J. W. Clark

Since Specialization

Citations

This map shows the geographic impact of J. W. Clark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. W. Clark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. W. Clark more than expected).

Fields of papers citing papers by J. W. Clark

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. W. Clark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. W. Clark. The network helps show where J. W. Clark may publish in the future.

Co-authorship network

The 25 scholars most cited alongside J. W. Clark, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J. W. Clark Line = papers co-authored together J. W. Clark links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The landscape of microbial associations in human cancer Science Translational Medicine ·Abraham Gihawi,Henry M. Wood,J. W. Clark,Justin O’Grady,Rosalind A. Eeles,David C. Wedge,Ling Yang,Gkikas Magiorkinis,Andrew Schache,Liam Masterson,А. Ю. Зализко,Tim R. Fenton,Terence M. Jones,Adrienne M. Flanagan,М А Крымова,Alex Rubinsteyn,Rachel Hurst,Colin S. Cooper,Daniel Brewer	2025	2
2	Building Data-Driven Pathways From Routinely Collected Hospital Data: A Case Study on Prostate Cancer JMIR Medical Informatics ·Joao H. Bettencourt‐Silva,J. W. Clark,Colin S. Cooper,Robert Mills,V. J. Rayward‐Smith,Beatriz de la Iglesia	2015	21
3	Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer Annals of Oncology ·Lawrence S. Blaszkowsky,David P. Ryan,Jackie Szymonifka,Darrell R. Borger,Andrew X. Zhu,J. W. Clark,E.L. Kwak,Harvey J. Mamon,Jill N. Allen,Hayer Georg,Paul C. Shellito,James C. Cusack,David L. Berger,Theodore S. Hong	2013	21
4	Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. Journal of Clinical Oncology ·Alice T. Shaw,B.Y. Yeap,Benjamin Solomon,Gregory J. Riely,A. John Iafrate,Geoffrey I. Shapiro,Daniel B. Costa,Mohit Butaney,S-H.I. Ou,Robert G. Maki,H. B. Danisman,Marileila Varella‐Garcia,Ravi Salgia,Keith D. Wilner,Kimary Kulig,Paulina Selaru,Yuan Tang,E.L. Kwak,J. W. Clark,D. Ross Camidge	2011	28
5	An evaluation of blood mRNA expression array signatures derived from unsupervised analyses in the identification of prostate cancers with poor outcome. Journal of Clinical Oncology ·David Olmos,J. W. Clark,Daniel Brewer,Lucy Lewitt,G. Attard,R Gini,Shahneen Sandhu,Andrea Zivi,Diletta Bianchini,M J.-M,Е А Чернов,L Rhoda Molife,S. B. Kaye,Catherine Parker,Colin Cooper,Nicholas J. Lawryk,Johann S. de Bono	2011	1
6	Identification of a small and lethal subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib by MET amplification. Journal of Clinical Oncology ·Jochen K. Lennerz,E.L. Kwak,Jian Shi,Stephen B. Fox,A. B. Ackerman,Kristin Bergethon,Gregory Y. Lauwers,James G. Christensen,Keith D. Wilner,Daniel A. Haber,Ravi Salgia,Y-J. Bang,J. W. Clark,Benjamin Solomon,A. John Iafrate	2011	6
7	A single-arm trial of panitumumab in cetuximab refractory KRAS wild-type colorectal cancer. Journal of Clinical Oncology ·Raymond Wadlow,Aram F. Hezel,Brian M. Wolpin,Liu Shufen,Lawrence S. Blaszkowsky,E.L. Kwak,Rawian Rafizah,Andrew X. Zhu,D. P. Ryan,J. W. Clark	2011	3
8	Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). Journal of Clinical Oncology ·D. Ross Camidge,Yung‐Jue Bang,E.L. Kwak,Alice T. Shaw,A. John Iafrate,Robert G. Maki,Benjamin Solomon,S-H.I. Ou,Ravi Salgia,Keith D. Wilner,Daniel B. Costa,Geoffrey I. Shapiro,P. LoRusso,J. M. Osete Albaladejo,Yi Tang,Katherine Ruffner,J. W. Clark	2011	102
9	Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology ·H. B. Danisman,E.L. Kwak,Alice T. Shaw,D. Ross Camidge,A. John Iafrate,Robert G. Maki,Benjamin Solomon,S-H.I. Ou,Ravi Salgia,J. W. Clark	2010	105
10	Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. Journal of Clinical Oncology ·Weiwei Tan,Keith D. Wilner,Colin Madrid,Chelsea Toone,Robert G. Maki,D. Ross Camidge,Benjamin Solomon,Dariusz Chru 'sci 'nski,Ravi Salgia,J. W. Clark	2010	40
11	Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer Annals of Oncology ·Peter C. Enzinger,D. P. Ryan,J. W. Clark,Alona Muzikansky,Craig C. Earle,Matthew H. Kulke,Jeffrey A. Meyerhardt,Lawrence S. Blaszkowsky,Andrew X. Zhu,P. Fidias,Michele Vincitore,Robert J. Mayer,Charles S. Fuchs	2009	16
12	Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Drivenbreakdown → Journal of Clinical Oncology ·Gerhardt Attard,Alison Reid,Timothy A. Yap,Florence I. Raynaud,Mitch Dowsett,S. Settatree,Mary Barrett,Christopher Parker,Vanessa Martins,Elizabeth Folkerd,J. W. Clark,Colin S. Cooper,Stan B. Kaye,David P. Dearnaley,Gloria Lee,Johann S. de Bono	2008	666
13	Phase II study of RAD001 in previously treated patients with metastatic pancreatic cancer Journal of Clinical Oncology ·Brian M. Wolpin,Aram F. Hezel,D. P. Ryan,Thomas A. Abrams,J. A. Meyerhardt,Lawrence S. Blaszkowsky,J. W. Clark,Benjamin Allen,Eileen Regan,Charles S. Fuchs	2008	9
14	O47 The prognostic impact of bone invasion in squamous cell carcinoma of the oral cavity R. R. Pate,Kun Gao,J. W. Clark,Claire O’Brien	2007	0
15	Phase I study of neoadjuvant bevacizumab, 5-fluorouracil, and radiation therapy followed by surgery for patients with primary rectal cancer Journal of Clinical Oncology ·Christopher G. Willett,Toru Aratani,D. Sahani,Masanobu Mino,J. W. Clark,D. P. Ryan,Andrew X. Zhu,Wiggin,Gregory Y. Lauwers,邓伦华 Deng Lunhua	2004	14
16	Current perspectives on locally advanced pancreatic cancer. PubMed ·Brian G. Czito,Christopher G. Willett,J. W. Clark,Vincent O. Okemwa	2000	20
17	Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. PubMed ·Noboru Sato,Julie Beitz,Jun Kato,Masahide Yamamoto,J. W. Clark,Peter A. Calabresi,Izabella Weber-Kaniuk,A. Raymond Frackelton	1993	121
18	The in vivo immunomodulatory effects of recombinant interferon gamma plus recombinant tumor necrosis factor-alfa. Journal of Clinical Oncology ·Walter J. Urba,William C. Kopp,J. W. Clark,John W. Smith,Ronald G. Steis,Christian G. Huber,Rhovi Mustaqimah,DL Longo	1991	7
19	Phase I Evaluation of Recombinant Tumor Necrosis Factor Given in Combination With Recombinant Interferon-Gamma Journal of Immunotherapy ·John W. Smith,W J Urba,J. W. Clark,Maktumkari Saidivya,Tiewei Chen,Stephen P. Creekmore,Kevin C. Conlon,Howard S. Jaffe,Ronald G. Steis	1991	19
20	Effect of ethanol tolerance on release of acetylcholine and norepinephrine by rat cerebral cortex slices Canadian Journal of Physiology and Pharmacology ·J. W. Clark,H. Kalant,F. J. Carmichael	1977	38

About J. W. Clark

J. W. Clark is a scholar working on Cancer Research, Oncology and Hepatology, having authored 26 papers that have together received 1.5k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (8 papers), Lung Cancer Treatments and Mutations (8 papers), Cancer, Hypoxia, and Metabolism (5 papers), Cancer Genomics and Diagnostics (4 papers), Gastric Cancer Management and Outcomes (4 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Molecular Biology Techniques and Applications (2 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (937 citations), Cancer Research (331 citations) and Oncology (490 citations). J. W. Clark has collaborated with scholars based in United States, United Kingdom and Myanmar. Frequent co-authors include Stan B. Kaye, Timothy A. Yap, Johann S. de Bono, David P. Dearnaley, Colin S. Cooper, Elizabeth Folkerd, Mitch Dowsett, Mary Barrett, Florence I. Raynaud and Alison Reid. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Science Translational Medicine, Canadian Journal of Physiology and Pharmacology and Journal of Immunotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact